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Introduction
The term “medical device” covers a wide range of technology.
According to the European Union (EU) directive 2007/47/EC, a
“medical device” is deﬁned as “any instrument, apparatus, appli-
ance, software, material or other article, whether used alone or in
combination, including the software intended by its manufacturer
to be used speciﬁcally for diagnostic and/or therapeutic purposes
and necessary for its proper application, intended by the manu-
facturer to be used for human beings for the purpose of diagnosis,
prevention, monitoring, treatment or alleviation of disease” [1].
Although medical devices and drugs both aim at restoring or
improving health, they are substantially different in their mode of
action. While drugs interact with biochemical pathways in the
human body, devices make use of a great diversity of actions and
reactions (e.g., radiation, heat, mechanical, electrical). In addi-
tion, devices may be used for both diagnostic and therapeutic
purposes. Thus, one may conclude that devices are fundamentally
different from drugs in nature and by deﬁnition.
The goal of health technology assessment (HTA) is to assess
the clinical and cost-effectiveness of existing and emerging
therapies—be those drugs or medical devices, or any other form
of medical technology—to inform the policy decisions of health-
care decision-makers on therapy access [2]. HTA is a two-stage
iterative process. First, a scientiﬁc assessment of the (clinical and
economic) evidence for a health technology is undertaken. Then,
based on this assessment, an appraisal of the evidence (together
with consideration of political, social, ethical factors) is made,
and a policy decision made, e.g., whether to fund or not to fund
the therapy in question. Increasingly, governments across the
world are mandating agencies such as the National Institute for
Health and Clinical Excellence (NICE) to issue national policy
guidelines on the use of drugs and medical devices based on such
a system of HTA and evidence-based appraisal.
Do the conceptual differences in drugs and medical devices
require a different framework of HTA or evidence-based
appraisal? In this article, we argue that although there are impor-
tant differences that need to be taken into account when assessing
the clinical and economic evidence base for medical devices—1)
the medical device licensing process; 2) the device-operator
interaction; and 3) the incremental innovation of medical
devices—these should not be seen as an obstacle to producing a
robust evidence base on the clinical and cost-effectiveness of
medical devices.
Medical Device Licensing
Drug licensing and market access approval by the Food and Drug
Administration (FDA) and international equivalents, such the
European Medicines Agency (EMEA) in Europe, require manu-
facturers to undertake randomized controlled (“phases II and
III”) trials to provide the regulator with robust evidence of their
drug’s efﬁcacy and safety. Nevertheless, the evidence hurdle for
licensing of medical devices is traditionally been much lower than
for pharmaceutical products [3]. For high-risk devices or new
devices for which there is no comparator product on the market
(class III devices), the FDA require manufacturers to submit a
premarket approval application, from which regulators deter-
mine whether there is sufﬁcient evidence of safety and effective-
ness for the intended uses [4]. In practice, this standard is often
met by small clinical trials in select groups of patients. The
studies often do not employ randomized designs, and the FDA
generally does not require manufacturers to collect long-term
efﬁcacy data [5]. HTA agencies and payers are therefore often
faced with the dilemma of assessing the clinical and cost-
effectiveness of medical devices in the face of absence or lack of
randomized controlled trial (RCT) evidence. For example, in two
recent technology appraisals by NICE of cochlear implants and
spinal cord stimulation for neuropathic back pain, manufactur-
ers submitted to NICE an evidence base of one and two RCTs,
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respectively. In contrast was the substantive body of nonrandom-
ized evidence for each of these technologies (e.g., 72 case series
for the use of spinal cord stimulation).
Variations in the evidence base available for devices implies
that unlike with drugs, ascertaining the clinical and cost-
effectiveness of medical devices will more often than not require
the consideration and analysis of data from observational
studies. This has direct implications regarding the level of sophis-
tication of the statistical methods required to robustly address
some of the issues commonly associated with observational data,
such as selection bias and confounding factors. In the context of
premarket evaluations of medical devices within the FDA’s
Center for Devices and Radiological Health, Bayesian methods
for the analysis of trial data have been proposed as an alternative
framework for evaluation [6]. The ﬂexibility of these methods
may make them particularly well suited to address many of the
issues associated with the assessment of clinical and economic
evidence on medical devices, such as learning effects, lack of
head-to-head comparisons between different devices, variations
in primary outcome measures, among others [7,8].
Device-Operator Interaction
The use of many medical devices, such as the two examples
described above, involve an interaction between the device, a
clinical procedure, and the clinician (or “operator”), where
important improvements in technical performance of a new tech-
nique may occur over time—a “learning curve” effect [9,10].
During the learning curve, errors and adverse outcomes are more
likely. This can distort the outcome results of a clinical trial if the
analysis does not account for learning effects explicitly. For
example, in Figure 1, a simulation is shown of comparison of the
use of medical device involving a clinical procedure to the man-
agement of the same condition by a drug. If the comparison were
to be conducted early in the experience of the clinician of the new
medical device (time A), then it would be concluded that drug
treatment performs better. Nevertheless, after a short period of
time and with increasing clinician experience, their performance
of the medical device increases markedly, such that by time B, the
performance of the medical device is superior to the drug. There
are few published examples of the use of medical devices where
the learning curve has been characterized (e.g. laproscopic gas-
trectomy and inguinal hernia repair) [10]. Nevertheless, the
potential interaction of a medical device and the operator needs
to be recognized and not be underestimated in the HTA process.
A variety of mathematical models—multilevel, latent curve, and
time series—have used to explore potential learning effects on
clinical and nonclinical data [10].
Incremental Innovation
Invariably, over the life of a medical device, incremental (some-
times stepwise) technological innovation takes place. For
example, in the case of spinal cord simulation, the last 10 to
15 years have seen progressively miniaturized devices, with
longer battery life, increasing number of electrode contacts with
increasing sophistication and ﬂexibility of choice in stimulation
parameters and settings [11]. As a result, the level of patient
beneﬁt (pain relief) has steadily improved over time with the use
of spinal cord stimulation. Although promoting an expedite
entrance of innovative products into markets might be justiﬁed as
a vehicle to enable individuals to beneﬁt from advances on health
technology at a faster pace, caution should be exerted to ensure
patients’ safety. Conditioning the licensing of innovative devices
on the conduct of robust pragmatic RCTs or well-designed obser-
vational studies might help preventing cases such as that of the
Sprint Fidelis implantable cardioverter-deﬁbrillator lead, found
in practice to be associated with an unexpectedly higher failure
rate than that suggested on the basis of bench testing [12].
Furthermore, increasing the quality and size of the evidence
based on effectiveness and cost-effectiveness of medical devices
will facilitate the HTA process by allowing the exploration of the
effectiveness of products within the same class.
Conclusions
We have highlighted that there are important differences between
medical devices and drugs that impact on the assessment of their
clinical and cost effectiveness. Nevertheless, as for drugs, quality
of manufacturing, safety, effectiveness, and cost-effectiveness
should be the four pillars underpinning the evaluation of medical
devices. We have argued that the differences in drugs and medical
devices have direct implications for trial design and statistical
methods to be used for the collection and the statistical analysis
of clinical and economic data on medical devices and also the
assessment component of the HTA process. Nevertheless, we
would also argue that the requirements for the policymaking
(appraisal) component of the HTA process are no different for
drugs and medial devices.
In HTA, health-care decision-makers and payers require a
common metric from the HTA process to appraise the evidence
for health-care technologies across different medical conditions.
The cost per quality of life in many settings has become that gold
standard metric, regardless of whether a policy maker is evalu-
ating a drug, medical device, or any other health-care technology.
HTA methods guidelines, including those of NICE and Canadian
Agency for Drugs and Technologies in Health, currently provide
no distinction in their approach to the scientiﬁc assessment of the
evidence of clinical of drugs and devices [13,14]. An important
future challenge for the HTA community is therefore to develop
methods to incorporate consideration of medical device-speciﬁc
issues, particularly the device-operator learning curve and incre-
mental innovation in device over time, when assessing their clini-
cal and cost-effectiveness.
An important recent development by the Centers for Medi-
care and Medicaid Services (CMS) in the United State has been
the development of a “coverage with evidence development”
policy [15]. If CMS determines that the information necessary for
a coverage determination is not available, Medicare will reim-





Figure 1 Hypothetical learning curves for medical device versus drug.
Adapted from Ramsay et al. (2001) [7].
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supported by the developers of the technologies or other related
groups. With these data, payers are better positioned to make
evidence-based determinations of whether new devices are “rea-
sonable and necessary.” This policy has stimulated a number of
pragmatic real-world RCTs for medical devices. Such conditional
decisions are being used in other setting. For example, returning
to the example of spinal cord stimulation, NICE have recently
announced an “only in research” recommendation for the use of
the device in patients with refractory angina and chronic limb
ischemia [16].
Is the HTA process for medical devices and drugs that differ-
ent? As has been argued here, differences in the nature of medical
devices and drugs (notably the operator-device learning curve
and incremental device innovation) do require the HTA commu-
nity to reﬂect on whether their current assessment methods
adequately take account of the speciﬁc features of medical
devices. In the meantime, and in the face of current and likely
future trends in licensing, “coverage with evidence” or “only in
research” policies, is an important output of HTA appraisals of
medical devices to incentivize the industry to collect the necessary
standard of evidence to appropriately assess their clinical and
cost effectiveness.
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